Promising pancreatic cancer drug daraxonrasib shows near-double survival, patients await expanded access

Amy Johnston, diagnosed with pancreatic cancer last year, has undergone chemotherapy and surgery and is now in a clinical trial that hopes to delay disease progression. She expects results by the end of the month and is prepared to seek another experimental therapy if needed.

The experimental drug daraxonrasib, developed by Revolution Medicines, nearly doubled overall survival in a recent trial. Researchers anticipate it will be approved as a second‑line treatment for pancreatic cancer.

Because the drug is not yet approved, it is being provided through an expanded access program that lets critically ill patients receive it outside of formal studies. However, strong interest and limited supply have left patients like Johnston uncertain about when they might actually obtain the medication.

The situation highlights the tension between exciting clinical data and the practical challenges of making new therapies available to those who need them most.